A narrative review from the National Psoriasis Foundation Medical Board found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may improve psoriasis severity, particularly in patients with obesity or type 2 diabetes, with reported Psoriasis Area and Severity Index (PASI) reductions of approximately 40% to 80% alongside improvements in metabolic and inflammatory markers. However, evidence is limited to small, short-term studies with inconsistent results, including a negative placebo-controlled trial, and largely restricted to populations with metabolic comorbidities. Mechanistic data suggest both weight-dependent and immunomodulatory effects, but larger randomized trials are needed before routine use in psoriasis can be established.